| REVIEW ARTICLE |
|
| Year : 2016 | Volume
: 31
| Issue : 2 | Page : 89-92 |
|
|
Pharmacovigilance in radiopharmaceuticals
Rishi Kumar1, Vivekanandan Kalaiselvan2, Rakesh Kumar1, Ravendra Verma2, Gyanendra Nath Singh2
1 Pharmacovigilance Division, Indian Pharmacopoeia Commission, National Coordination Centre-Pharmacovigilance Programme of India, India
2 Pharmacovigilance Division, Indian Pharmacopoeia Commission, Ghaziabad, Uttar Pradesh, India
Correspondence Address:
Rishi Kumar
Indian Pharmacopoeia Commission, National Coordination Centre-Pharmacovigilance Programme of India, Ghaziabad, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0972-3919.178252
|
|
|
Indian Pharmacopoeia Commission is Committed for maintaining the standards of drugs including Radiopharmaceuticals (RPs) by publishing Indian Pharmacopoeia. These RPs are being used in India for diagnostic or therapeutic purpose. RPs though contain relatively small quantities of active ingredient and administered in small volumes could cause some adverse reactions to the patients. The objective of presenting this article is to introduce the system of adverse drug reaction reporting to the nuclear medicine fraternity who are dealing with RPs. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
